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Aim: To assess the attitudes and preferences of patients currently being treated for depression 
or anxiety disorders with traditional oral antidepressants relative to a placebo orodispersible 
(ODT) formulation of escitalopram.
Methods: This was an open study collecting patient-reported outcome data from patients with 
anxiety or depression that were treated with oral antidepressant medication on Day 0 before and 
after receiving a single placebo ODT, and on Day 3 or 4 after receiving two further daily doses 
of placebo ODT. Patients aged 18–80 years who were currently receiving treatment with oral 
antidepressants were recruited from general practice and by advertising. Patients with significant 
symptoms of anxiety or depression (scoring $9 on either the depression or anxiety subscales 
of the Hospital Anxiety and Depression Scale) were included in the study.
Results: A total of 150 patients were enrolled in and completed the study. About 37% of the 
patients had had trouble with swallowing tablets, and patients with higher depression scores 
reported more general swallowing problems than those with lower scores (P = 0.002). Most 
patients (75.3%) believed that an ODT might work faster but that it would make no difference 
to the effectiveness of the medication (63.1%) or the number of side effects (81.3%). About 
96% of the patients reported experiencing a pleasant taste following the placebo ODT, although 
seven patients did not like its taste or aftertaste. This study found that 80.7% of patients reported 
that the tablets were easy or very easy to get out of the packaging.
Conclusion: Based on the results of the placebo version of escitalopram ODT, the escitalopram 
ODT is likely to be well accepted by patients suffering from anxiety or depressive symptoms.
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Introduction
Escitalopram is a highly selective serotonin reuptake inhibitor (SSRI) used for the 
treatment of depression and anxiety disorders. It is available as oral coated tablets of 
5, 10, and 20 mg. A new formulation of an orodispersible tablet (ODT) containing 
escitalopram has been developed and its pharmacokinetics and pharmacodynamics 
are similar to that of the existing immediate release tablets.1
While obvious benefits for the formulation exist for specific populations such as 
patients with swallowing difficulties or specific diseases such as Parkinson’s,2 the 
benefits for more general groups of patients or for specific subgroups have not been 
fully evaluated. Although healthy male subjects expressed a preference for ODT 
escitalopram,1 the preferences of patients suffering from depression or anxiety have 
not been investigated.
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Swallowing problems affecting medication taking and 
compliance are more common than is often recognized in 
general practice.3,4 A study by Andersen et al found that 
26% of a Norwegian general practice population reported 
difficulties swallowing tablets, with women having problems 
twice as frequently as men.5 Compliance with medication is 
a serious problem in patients with depression and may be 
improved by the use of ODT tablets, which eliminate the need 
to swallow a tablet.6,7 Advantages of the new formulation are 
also likely to lie in patient attitudes and preferences and in 
the impact that these have on areas such as stigma, utility, 
and patient perception that, rightly or wrongly, ODT tablets 
have improved efficacy and speed of onset.
Studies have been undertaken in focus groups to assess 
patient preferences for ODT versus oral tablet and the 
acceptability of the formulation. However, attitudes and 
preferences are heavily influenced by psychological status 
and personality traits. Therefore, it was important to assess 
the new formulation in patients currently being treated for 
depression or anxiety disorders. The main aim of this open 
study was to assess the attitudes and preferences of patients 
currently being treated for depression or anxiety disorders 
towards a new ODT formulation in comparison to their 
current treatment with a traditional oral antidepressant. The 
placebo version of escitalopram ODT was used as the study 
medication rather than active medication.
Methods
Study design
This was an open study collecting patient-reported outcome 
data from patients with anxiety or depression. Data were 
collected on Day 0 (both before and after receiving a single 
placebo ODT) and on Day 3 or 4 after receiving two fur-
ther daily doses of placebo ODT, so that their use could be 
assessed in normal circumstances. This study was performed 
in compliance with good clinical practice. Since this study 
was designed to assess patient preferences for the ODT, the 
attitudes and the acceptability of the formulation to patients 
currently being treated for depression or anxiety disorders 
was assessed through the use of five patient-reported outcome 
questionnaires. The placebo version of escitalopram ODT was 
used as the study medication rather than active medication.
Patients
Patients aged 18 to 80 years who were currently receiving 
treatment with oral antidepressant drugs were recruited from 
general practice and by advertising. These patients were 
invited to participate in the study and informed consent 
was obtained. The Hospital Anxiety and Depression Scale 
(HADS)8 was administered to distinguish between patients 
whose primary symptoms were related to anxiety ($9 on 
the anxiety subscale, HADS-A) and those whose primary 
symptoms were related to depression ($9 on the depression 
subscale, HADS-D). The HADS is a patient-reported scale 
that includes these two subscales, each of which is composed 
of seven items that are each rated from 0 to 3. The patient 
is required to indicate the response that most accurately 
reflects the way he/she has felt over the last few days. The 
scores for questions relating to anxiety and depression are 
added to obtain the total scores for anxiety and depression. 
Patients scoring 9 or more on either the depression or anxiety 
subscales were included in the study. Only patients willing 
to participate in a questionnaire, take a placebo tablet, and 
complete a follow-up questionnaire were considered suitable 
for enrolment. Patient demographic data was collected prior 
to completing the questionnaires.
Treatment
The study medication was identical in composition and 
appearance to escitalopram ODT apart from the lack of 
active substance, which was replaced by inert filler. The 
study medication provided by H Lundbeck A/S (Valby, 
Denmark) was manufactured, packed and shipped according 
to good manufacturing practice (GMP) and good distribution 
practice (GDP) standards. Supplies were provided in blister 
packs of six tablets. Participants were requested to return 
all unused tablets to the study site for destruction. Patients 
were administered a single placebo ODT under supervision 
on Day 0, and the time of the administration was recorded. 
Each patient was given two ODTs to self-administer as a 
single tablet on Day 1 and 2. Compliance for this period was 
recorded during the telephone interview when patients were 
asked “Did you take both tablets as instructed?”
Patient-reported outcome measurements
Three pre-dose questionnaires were used during this study: 
patient attitudes towards their illness and current medica-
tion, attitudes to medicines, and a medicine swallowing 
questionnaire. Immediately after the patient took a single 
dose of placebo ODT escitalopram, an attitudes/preference 
questionnaire (post-placebo ODT) was completed. A second 
questionnaire was conducted by telephone following use of 
the additional placebo tablets; this assessed any changes 
that had occurred in the patients’ attitudes after they had had 
additional time to consider the questions, use the ODT tablets, 
and discuss their use with relatives and friends.
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Statistical methods
Descriptive statistics were used to summarize the data. The 
intention to treat (ITT) analysis set, which consisted of all 
enrolled patients, was used to analyze all patient-reported out-
come variables. Kruskal–Wallis tests were used to investigate 
relationships between age groups and anxiety and depression 
scores. The association between age groups and responses to 
the medicines swallowing questionnaire and patient attitude 
questions were assessed using chi-squared tests. All analyses 
were done using Minitab (v16; Minitab Inc, State College, 
PA) at a 5% significance level.
Results
Patient disposition
A total of 150 patients were enrolled in and completed the 
study. The first patient entered the study in July 2011 and 
the last patient completed the study in August 2011. The 
demographic characteristics of study patients are summa-
rized in Table 1.
Baseline characteristics
The HADS scores of patients are summarized in Table 2. 
A total of 105 patients (70% of total patients) were cat-
egorized as having moderate to severe anxiety (.11 on 
the anxiety subscale), and 77 (51%) were categorized as 
having moderate to severe depression (.11 on the depres-
sion subscale). HADS-A scores of $9 were recorded for 
135 patients (90%) and a HADS-D score of $9 was recorded 
for 110 patients (73.3%), with 95 patients (63.3%) being anx-
ious and depressed, 40 patients (26.7%) being anxious but 
not depressed, and 15 patients (10.0%) being depressed but 
not anxious. No patients were assessed by the HADS meth-
odology as being both non-anxious and non-depressed.
All 150 patients were taking antidepressant medication 
upon enrolment into the study. The most commonly pre-
scribed antidepressant medications were citalopram (33.3%) 
and fluoxetine (22.7%). In addition, three patients (2%) were 
recorded as taking anxiolytics; two patients (1.3%) took diaz-
epam, and one patient (0.7%) took buspirone. Most patients 
(76%) had been taking their antidepressant medication for 
more than 6 months. Concomitant medication taken after 
study entry was not recorded.
Treatment compliance was 100% for the single ODT 
administered in the clinic under supervision. Compliance was 
also 100% for days 1 and 2, as assessed from the responses 
given in the post-interview telephone questionnaire.
Patient reported outcomes
Tablet swallowing questionnaire
While 61 patients (40.7%) in this study reported no prob-
lems swallowing tablets, 56 patients (37.3%) had problems 
swallowing medications, and a total of 115 patients (76.7%) 
indicated a preference for a tablet that was easy to swallow. 
Patients had previously used several methods to make a tablet 
easier to swallow, with 22.7% having crushed the tablet, 7.3% 
having emptied the contents of a capsule, 8.7% having tried to 
dissolve medication in water, and 24.7% having used another 
method, usually dividing or breaking the tablet.
Patient attitude on illness and current medication
Patients were aware of the mental illnesses they were 
s  uffering from and most reported that they suffered from 
Table 1 Demographic characteristics, iTT analysis set (n = 150)
n (%)
Age (years)
  18–30 16 (10.7%)
  31–45 48 (32.2%)
  45–60 62 (41.6%)
  60–80 23 (15.4%)
  Missing 1
Gender
  Male 51 (34.0%)
  Female 99 (66.0%)
Race
  Caucasian 148 (99.3%)
  Other 1 (0.7%)
  Missing 1
Note: Percentages are expressed as percentage of patients with data.
Table 2 hospital anxiety and depression (hADS) scale scores, 
iTT analysis set (n = 150)
Parameter
Anxiety: total hADS-A score
  Median 13
  Range 3–21
  Q1, Q3 10, 15
Category, n (%)
  Abnormal 105 (70%)
  Borderline normal 33 (22%)
  normal 12 (8%)
Depression: total hADS-D score
  Median 11
  Range 1–14
  Q1, Q3 8, 14
Category, n (%)
  Abnormal 77 (51.3%)
  Borderline normal 44 (29.3%)
  normal 29 (19.3%)
Notes:  Categories  of  anxiety  and  depression  levels  were  defined  based  on   
hADS  scale  scores  in  which  0–7  =  normal,  8–10  =  borderline  abnormal,  and   
11–21 = abnormal.
Abbreviations: hADS-A, hospital anxiety and depression scale (anxiety); hADS-D, 
hospital anxiety and depression scale (depression); iTT, intention to treat.
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more than one condition. Moderate to severe depression 
(reported in 59.3% of patients) and anxiety (56.0%) were 
the most c  ommonly reported conditions, with 30% report-
ing stress and 18.7% reporting bereavement reaction. The 
  majority of patients (86%) had long-standing illness (more 
than 1 year) and 64.4% had been taking antidepressant 
medication for more than one year. Most patients (94%) 
had told family or friends about their illness and 71.3% 
reported that they were getting at least a fair amount of 
support from them.
Morning was the most commonly reported time for taking 
antidepressant medication in this study with 58.7% of patients 
taking their tablets at this time. Their reported compliance 
was high with 44% stating that they never missed a tablet and 
54% skipping a tablet only occasionally. The main reasons 
reported to potentially make patients less likely to regularly 
take their treatment were side effects (36%) and uncertainty 
regarding efficacy (17.3%). There were 60 (40.3%) patients 
who had missed work or daily activities for .5 days due to 
their illness in the previous month, but 51 (34.2%) who had 
not missed a day.
Attitudes to medicines – pre-dose
Patients were asked to rank the importance of nine tablet 
characteristics on a scale from 1 (very important) to 9 (not 
important at all). There was a significant difference between 
the nine ideal tablet characteristics (Kruskal–Wallis test, 
P , 0.001). The most important ideal characteristics (all 
with a median score of 1) were the need to take a tablet less 
frequently, that it was easy to swallow, that it was effective 
at treating the illness, that it have no serious side effects even 
if they are rare, that it have no side effects at all, and that it 
relieved symptoms quickly. The lowest ranking was for ‘the 
tablet feels and looks new and modern’ (median score of 9). 
A pleasant taste (median score of 3) and ease of getting out 
of the packaging (median score of 2) were also rated less 
important than other characteristics.
Thirty-five patients (23.5%) had previously taken an 
orodispersible tablet. About half (50.7%) of all patients 
thought that a tablet that melted in the mouth would make 
it easier to take medication regularly. The convenience of 
being able to take a tablet while out of the house, the fact 
that it does not need to be swallowed, and that it could be 
taken without work colleagues/acquaintances seeing them 
taking it were perceived as advantages of an orodispersible 
antidepressant tablet by 93.8%, 79.1%, and 72.3% of patients, 
respectively. Most patients (75.3%) believed that an ODT 
might work faster but that it would make no difference to 
the e  ffectiveness of the medication (63.1%) or the number 
of side effects experienced (81.3%).
Attitudes to medicines – post placebo ODT
A high proportion (96%) of the patients reported experienc-
ing a pleasant taste following the placebo ODT and 80.7% 
found that the tablets were easy or very easy to get out of 
the packaging. No patient had any difficulty with picking 
up the tablet and placing it in the mouth, with 77.3% of 
patients finding it a very easy process. Having taken an 
ODT placebo, 81.9% of patients thought that a real ODT 
tablet would work more quickly than their existing tablet 
and 81.3% expressed a preference for this type of tablet. 
Of the 126 patients (84%) who expressed a definite prefer-
ence (“yes”, 95 patients; “no”, 31 patients) for this type of 
tablet, a significantly higher proportion said they would 
be more likely to take this type of tablet every day (75.4% 
versus 24.6%, Z-test, P , 0.001). Four patients commented 
that they would have preferred/suggested another flavor 
and three patients found that the tablet had a chalky or 
powdery taste.
Post-interview telephone questionnaire
Most patients (96%) had not changed their attitude to dis-
cussing their illness with family and friends or taking their 
medication regularly since the post-placebo interview, and 
the taste responses given in the post-interview telephone 
questionnaire were similar to those obtained in the post-
placebo questionnaire. Thirty-five patients (23.3%) found 
it slightly difficult or very difficult to get the tablets out of 
the packaging compared with 25 patients (16.7%) after the 
first dose. Responses to the question “Would you prefer 
your tablets to be like this?” were comparable with those 
obtained after single dose, although there was an increase 
in the number of patients preferring to stay on their existing 
medication (increased from six to 13 patients), and fewer 
patients responded that they would be less likely to take 
this type of tablet every day (decreased from 31 patients to 
21 patients).
Additional statistical analyses
There were no clear associations between age and the 
responses to the medicine swallowing questions, although 
there was evidence of an association between depression 
and swallowing problems (Pearson χ2 statistic of 9.171, 
P = 0.002). Patients with depression scores $9 were more 
likely to report having swallowing problems swallowing food 
than those with depression scores ,9.
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Discussion
All patients in this open study were taking antidepressant 
medication and the majority had been doing so for more than 
a year. The severity of reported symptoms in patients who 
were predominantly on long-term antidepressant treatment 
may indicate a selected population who volunteered for this 
study, nevertheless it reflects the high symptomatology of 
patients on long-term antidepressant therapy previously 
reported in an earlier “well-being” study.9 However, the study 
population is considered to be a representative sample of the 
intended target population. The sample size of 150 patients 
was also considered to be sufficient to obtain meaningful 
descriptive data.
Regan et al reported a higher proportion of patients with 
severe mental health problems complaining of swallowing 
difficulties than would be expected in the general population.10 
The current study also found evidence of an association 
between depression severity and swallowing problems, 
with patients with higher depression scores reporting more 
general swallowing difficulties than those with lower scores. 
Thirty-seven percent of the patients in the current study had 
trouble swallowing tablets and more than one-fifth of patients 
reported that they had at some time crushed their tablets or 
emptied out the capsule before taking it. While these figures 
may appear high, they accord well with those reported by 
Llorca4 and the fact that over one-fifth of patients had taken 
measures to circumvent the problem suggests that swallowing 
problems may be significant. Furthermore, the current study 
suggests that ease of swallowing is an important characteris-
tic in an ideal tablet, with most patients indicating a definite 
preference for a tablet that was easy to swallow.
Compliance with medication is a significant problem in 
most chronic diseases and particularly so for depression. The 
impact of the formulation of the medication on compliance 
cannot be determined with confidence from this study but 
a significantly higher proportion of patients thought that a 
tablet that melted in the mouth would make it easier to take 
regularly than those who thought that it would not make a 
difference, which is in accord with results reported by Roose11 
and Benkert et al12 for mirtazapine. Overall, the results dem-
onstrate that there is a real need for an antidepressant tablet 
that is easy to take.
The general ease of use of an orodispersible antidepres-
sant tablet was further demonstrated by the patients’ report-
ing that these tablets are preferred as they do not need to be 
swallowed, are convenient to take when out of the house, and 
can be taken without work colleagues/acquaintances seeing 
them doing so. Side effects are one of the main reasons that 
patients may be less likely to take their treatment regularly, 
and the patients in the current study felt that an ideal tablet 
would have no serious side effects even if they are rare, or 
have no side effects at all. However, patients were realistic 
in their expectations of orodispersible tablets. Prior to tak-
ing a placebo ODT, most patients did not expect this type of 
tablet to affect the incidence of side effects or the effective-
ness of the medication, but believed that an antidepressant 
orodispersible tablet might work faster.
Morning was the most commonly reported time for 
taking antidepressant medication. Having taken a placebo 
ODT, most patients thought that a real (active escitalopram) 
tablet would work more quickly than their existing tablet and 
expressed a preference for this type of tablet. The process 
of getting the tablets out of the packaging was an easy task 
for the vast majority of patients. Patients were also likely 
to enjoy the experience of taking the tablets as almost all 
patients thought that the placebo version of escitalopram 
ODT had a pleasant taste, although a few did not like its 
taste or aftertaste.
Patients generally expressed similar attitudes and prefer-
ences before and after taking the placebo version of the ODT 
and also after having had time to reflect on their thoughts 
after taking two further doses at home. However, there was 
some evidence that more patients found it slightly difficult 
or very difficult to get the tablets out of the packaging in the 
home environment than they did after taking the first dose 
under supervision.
There were limitations with the current study. The 
patients were recruited through general practitioner referral 
and advertising, and there may be some recruitment bias with 
motivated patients more likely to respond to these methods of 
recruitment. In addition, the patients were asked to complete 
five patient-reported outcome questionnaires with a total of 
52 questions, and they may not be fully focused on correctly 
and honestly answering such a large number of questions. 
The placebo version of escitalopram was used as the study 
medication and there may be problems with extrapolating 
some of the results such as taste perception to the active 
escitalopram ODT.
Conclusion
The majority of patients in this study had long-standing 
anxiety or depression and they had been taking antidepressant 
medication for more than 1 year. Their reported compliance 
with taking antidepressant medication was high. Family or 
friends were generally aware of their illness and the majority 
of patients were getting some support from them.
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Many patients had problems swallowing medications 
and most reported that they would prefer to use a tablet that 
is easy to swallow. Patients with higher depression scores 
may have more general swallowing problems than those with 
lower depression scores.
The escitalopram ODT is likely to be well accepted by 
patients suffering from anxiety or depressive symptoms 
based on the results of the placebo version used in the   current 
study. Most patients reported that the placebo v  ersion of 
escitalopram ODT had a pleasant taste, although a few did 
not like the taste or the aftertaste of the product. Patients 
generally preferred this type of tablet to the t  raditional 
f  ormulations and felt that they would be more likely to 
take it regularly. Overall, they expected an active ODT to 
work more quickly than their existing tablet but did not 
expect an ODT to make any difference to the incidence of 
side effects.
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